Fallopian Tube

Treatment Stage Protocol Title ClinicalTrials.Gov Link Penn Research Coordinator Am I Eligible? 
Recurrent CAPRI: Combination ATR and PARP Inhibitor (CAPRI) Trial with AZD6738 and Olaparib in Recurrent Ovarian Cancer NCT03462342 Shavon Rochester Eligibility Criteria 

STRO+bev: A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody DrugConjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)

NCT05200364 Destany Fields

Eligibility Criteria 

Enrollment on Hold

Recurrent ATRN: A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral ATRN-119 in Patients with Advanced Solid Tumors NCT04905914 Andrea Standish, RN Eligibility Criteria
Recurrent GOG 3066: A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT04814108 Kristina Powell Eligibility Criteria 
Recurrent GOG 3063: A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7) NCT05092360 Shavon Rochester Eligibility Criteria
Recurrent STAR-101: A Phase 1 Study of SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR, in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma NCT05568680 Andrea Standish, RN Eligibility Criteria
Recurrent NP-G2-044-P2-01: NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies NCT05023486 Shavon Rochester Eligibility Criteria
Recurrent NRG-GY031: A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer NCT05950464 Christine Pae Eligibility Criteria
Recurrent A Phase 1/2 Study of CPI-0209 in Patients with Advanced Solid Tumors and Lymphomas NCT04104776 Destany Fields Eligibility Criteria
Recurrent First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1047 in subjects with malignant solid tumors NCT05180474 Katie Hayes, RN Eligibility Criteria
Recurrent A phase II evaluation of maintenance therapy combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer NCT05887609 Kristina Powell Eligibility Criteria